PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

A61K 35/74, 38/16, 39/395, 48/00

A3 (11) International Publication Number: WO 00/15175

(43) International Publication Date: 23 March 2000 (23.03.00)

(21) International Application Number: PCT/SE99/01560 (81) Designated States: AE, AL, A.

(22) International Filing Date: 8 September 1999 (08.09.99)

(30) Priority Data:

9803098-4 10 September 1998 (10.09.98) SE 60/135,798 24 May 1999 (24.05.99) US

(71)(72) Applicants and Inventors: ARENCIBIA, Ignacio [CU/SE]; Historiegränd 20A, 102, S-907 34 Umeå (SE). SUNDQVIST, Karl-Gösta [SE/SE]; Skäluddsvägen 16, S-178 32 Ekerö (SE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(88) Date of publication of the international search report:

13 July 2000 (13.07.00)

(54) Title: USE AS AN ACTIVE SUBSTANCE OF MOLECULES BINDING TO BETA-1-INTEGRIN WITH THE CAPACITY TO KILL CELLS

(57) Abstract

The present invention relates to the use as an active substance of molecules binding to β_1 -integrins and with the capacity to kill cells having β_1 -integrins for production of pharmaceuticals for treatment of conditions dependent on cells having β_1 -integrins such as cancer and conditions dependent on T lymphocytes and fibrotic conditions. Especially the invention relates to the use of Invasin (Inv) from Yersinia (Yer) species, subfragments, variants, and peptides thereof, microorganisms producing invasin and invasin like substances and antibodies binding β_1 -integrins and with the capacity to kill cells having β_1 -integrins.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	$\mathbf{U}\mathbf{Z}$	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

International application No.

PCT/SE 99/01560

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 35/74, A61K 38/16, A61K 39/395, A61K 48/00 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9613250 A1 (AMGEM INC.), 9 May 1996 (09.05.96), page 4, line 20 - line 34; page 6, line 20 - line 26; page 9, line 3 - line 24, page 12, line 8 - line 18; page 13, line 4 - line 31; page 15, line 24 - line 26; page 19, line 8-16	1-4,6,8-10
X	Science, Volume 267, February 1995, Nancy Boudreau et al, "Suppression of ICEand Apoptosis in Mammary Epithelial Cells by E xtracellular Matrix", page 891 - page 893, see abstract	1-2,4-6,8

X	Further documents are listed in the continuation of Box	C.	X See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority
"A"	document defining the general state of the art which is not considered to be of particular relevance		date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	erlier document but published on or after the international filing date	"X"	document of particular relevance: the claimed invention cannot be
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other		considered novel or cannot be considered to involve an inventive step when the document is taken alone
	special reason (as specified)	"Y"	document of particular relevance: the claimed invention cannot be
″0″	document referring to an oral disclosure, use, exhibition or other means		considered to involve an inventive step when the document is combined with one or more other such documents, such combination
″P″	document published prior to the international filing date but later than		being obvious to a person skilled in the art
	the priority date claimed	"&"	document member of the same patent family
Date	e of the actual completion of the international search	Date of	of mailing of the international search report
			2 8 -03- 2000
14	March 2000		2 0 00 2000
Nan	ne and mailing address of the ISA/	Autho	rized officer
Swe	edish Patent Office		
Вох	: 5055, S-102 42 STOCKHOLM	Carl	-Olof Gustafsson/EÖ
Face	simile No. + 46 8 666 02 86	Teleph	none No. +46 8 782 25 00

International application No.

PCT/SE 99/01560

		101/32 33/	
C (Continu	nation). DOCUMENTS CONSIDERED TO BE RELEVANT	· · · · · · · · · · · · · · · · · · ·	_
Category*	Citation of document, with indication, where appropriate, of the rele	vant passages	Relevant to claim No
х	Dialog Information Services, File 155, MEDLIN MEDLINE accession no. 08950105, Mitra RS Apoptosis in keratinocytes is not depende induction of differentiation"; & Lab Inve 1997, 76 (1) p99-107, ISSN 0023-6837, see	et al: nt on st Jan	1-2,4-6,8
P,X	US 5846536 A (MINA J. BISSELL ET AL), 8 December 1998 (08.12.98), see abstract; 16, lines 3-7	column	1-2,4-6,8

International application No. PCT/SE 99/01560

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows: see next sheet
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

International application No. **PCT/SE 99/01560**

Unity of invention is lacking

According to PCT Rules 13.1 and 13.2, an international application shall relate to one invention only or a group of inventions linked by one or more of the same corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art.

In Your application the following inventions have been found:

- 1. Use as an active substance of a molecule binding to beta-1-integrin, such as the invasin protein from Yersinia, possibly coupled to an antibody. This invention also discloses a pharmaceutical composition comprising the active substance and methods of killing T-lymphocytes and tumor cells. The special technical feature of this invention is the use of invasin. This invention is disclosed in claims 1-4, 6 and 8-10.
- 2. Use as an active substance of a monoclonal antibody or a hybrid antibody binding to and killing cells with beta-1-integrins. The special technical feature of this invention is the use of a monoclonal or hybrid antibody with the ability to kill cells having beta-1-integrin. This invention is disclosed in claims 1 and 5.
- 3. Use in gene therapy of a molecule binding to beta-1-integrin wherein the invasin gene sequence is used. The special technical feature of this invention is the use of the invasin gene sequence. This invention is disclosed in claims 1 and 7.

The three inventions are not linked by any common "special technical feature". Thus, the inventions lack unity. The first and second inventions have been searched.

Information on patent family members

International application No.

02/12/99 | PCT/SE 99/01560

				2/12/99	PU1/3E	33/01200
Patent document cited in search repo	rt	Publication date		Patent family member(s)		Publication date
9613250	A1	09/05/96	AU	4010395	A	23/05/96
S 5846536	A	08/12/98	NONE			
S 5846536 	A 	08/12/98 	NONE			